Lupin has recalled 55,348 bottles of generic amlodipine besylate tablets in the US while Cadila Healthcare recalled 14,808 bottles of generic bromocriptine mesylate 5-mg capsules.
The USFDA has categorised the Lupin recall as Class III, meaning the drug is unlikely to cause any adverse effect on health but violates labelling or manufacturing laws.
The Cadila recall, categorised as Class-II, may cause medically reversible adverse health consequences.